IMRX (STOCKS)
Immuneering Corporation Class A Common Stock
$5.776000
+0.256000 (+4.64%)
Prev close: $5.520000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Benjamin J. Zeskind
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $369.17M
- Employees
- 54
- P/E (TTM)
- -4.00
- P/B (TTM)
- 1.63
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $59.38M |
| Research and Development | $42.05M |
| Other Operating Expenses | $17.33M |
| Operating Income/Loss | -$59.38M |
| Income/Loss From Continuing Operations After Tax | -$56.02M |
| Income/Loss From Continuing Operations Before Tax | -$56.02M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$56.02M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$56.02M |
| Net Income/Loss Available To Common Stockholders, Basic | -$56.02M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.27 |
| Diluted Earnings Per Share | -$1.27 |
| Basic Average Shares | 44,011,830 |
| Diluted Average Shares | 44,011,830 |
| Assets | $231.99M |
| Current Assets | $176.25M |
| Noncurrent Assets | $55.74M |
| Fixed Assets | $938.48K |
| Other Non-current Assets | $54.80M |
| Liabilities | $13.50M |
| Current Liabilities | $10.07M |
| Accounts Payable | $1.54M |
| Other Current Liabilities | $8.53M |
| Noncurrent Liabilities | $3.43M |
| Equity | $218.48M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $218.48M |
| Liabilities And Equity | $231.99M |
| Net Cash Flow From Operating Activities | -$45.34M |
| Net Cash Flow From Operating Activities, Continuing | -$45.34M |
| Net Cash Flow From Investing Activities | -$88.74M |
| Net Cash Flow From Investing Activities, Continuing | -$88.74M |
| Net Cash Flow From Financing Activities | $226.58M |
| Net Cash Flow From Financing Activities, Continuing | $226.58M |
| Net Cash Flow | $92.50M |
| Net Cash Flow, Continuing | $92.50M |
| Comprehensive Income/Loss | -$55.94M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$55.94M |
| Other Comprehensive Income/Loss | -$55.94M |
| Other Comprehensive Income/Loss Attributable To Parent | $81.33K |